Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...

WHO has released its first unified clinical guidelines for managing dengue, Zika, chikungunya, and yellow fever, aiming to ...

As the United States market navigates a complex landscape marked by trade policy uncertainties and fluctuating economic indicators, major indices like the Dow Jones Industrial Average and S&P 500 ...

The Sri Lanka Pharmaceutical Manufacturers’ Association (SLPMA), in a historic step, has issued a powerful national call to ...